Equillium (NASDAQ:EQ – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on ...

These experts highlighted the significance of Lusvertikimab’s clinical trial results within the current research and therapeutic landscape. They also discussed how these advancements address unmet ...

ROME (AP) — Pope Francis remained in stable condition and didn’t need any mechanical ventilation Sunday, the Vatican said. It was a sign that he had overcome the possible complications from a ...

Biocon has made strides in novel biologics, with the introduction of India’s first indigenously produced monoclonal antibody, Nimotuzumab, and Itolizumab for treating psoriasis. The company continues ...

Itolizumab demonstrated clinical efficacy after ... experts in the field of inflammatory bowel disease (IBD). "The CD6-ALCAM pathway is elevated in gastrointestinal inflammation and is associated ...

Equillium is on the cusp of taking CD6-targeting antibody itolizumab into phase 3 testing for GvHD, a potentially life-threatening complication of transplant procedures, and is waiting for results ...